

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

O I P E MAR 28 2005 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.		Complete if Known	
Substitute for form 1449A/PTO		<i>Application Number</i>	10/814,025
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Filing Date</i>	March 31, 2004
(Use as many sheets as necessary)		<i>First Named Inventor</i>	Rasmussen et al.
		<i>Art Unit</i>	1636
		<i>Examiner Name</i>	Sullivan, Daniel M.
Sheet	1	of	8
		<i>Attorney Docket Number</i>	GC22.4-CON2

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	6/29/05
-----------------------	---	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 8

**Complete if Known**

<i>Application Number</i>	10/814,025
<i>Filing Date</i>	March 31, 2004
<i>First Named Inventor</i>	Rasmussen et al.
<i>Art Unit</i>	1636
<i>Examiner Name</i>	Sullivan, Daniel M.
<i>Attorney Docket Number</i>	GC22.4-CON2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DS</i>		AERTS, J.M.F.G. et al., "Glucocerebrosidase, a Lysosomal enzyme that does not undergo oligosaccharide phosphorylation", Biochimica et Biophysica Acta, 1988, pp. 303-308.	
		BERGH, M. et al., "Processing and Glycosylation of Human Glucocerebrosidase Expressed in Insect Cells and in Chinese Hamster Ovary Cells", Absts. Paper. Am. Chem. Soc. 200 <sup>th</sup> Meet. BIOT 109, 1990.	
		BERGH, M. et al., "Heterologous Expression of Human Glucocerebrosidase: Glycosylation, Processing and Secretion", Absts. Paper. Am. Chem. Soc. 199 <sup>th</sup> Meet. BIOT 51, 1990.	
		BETTGER, W.J. et al., "Rapid clonal growth and serial passage of human diploid fibroblasts in a lipid-enriched synthetic medium supplemented with epidermal growth factor, insulin, and dexamethasone", Proc. Natl. Acad. Sci USA, 1981, Vol. 78, pp. 5588-5592.	
		BIAGLOW, J.E., "Oxygen, Hydrogen Donors and Radiation Reponse - The Oxygen Effect with Cells", Advances in Exp. Medicine and Biology, Hyperthermia, Bicher and Bruley, eds., Plenum Press, NY, 1982, Vol. 157, pp. 147-175.	
		BRADY, R.O. et al., "Demonstration of a Deficiency of Glucocerebroside-cleaving Enzyme in Gaucher's Disease", J. Clin. Invest., 1966, Vol. 45, Issue 7, pp. 1112-1115.	
		BRADY, R.O. et al., "Enzyme Replacement Therapy – Specific Targeting of Exogenous Enzymes to Storage Cells", Membranes and Transport, 1982, Vol. 2, pp. 587-592.	
		BRADY, R.O. et al., "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher Disease", J. Inher. Metab. Dis., 1994, Vol. 17, pp. 510-519.	
		BRADY, R.O. et al., "Status of Enzyme Replacement Therapy for Gaucher Disease", Birth Defects: Original Article Series, 1980, Vol. XVI, No. 1, pp. 361-368.	
		BRADY, R.O. et al., "The Metabolism of Glucocerebrosides. I. Purification and Properties of a Glucocerebroside-Cleaving Enzyme From Spleen Tissue", J. Biol Chem., 1965, Vol. 240, No. 1, pp. 39-43.	
<i>DS</i>		BRADY, R.O., "The Sphingolipidoses", The New England Journal of Medicine, 1966, Vol. 275, Issue 6, pp. 312-317.	

Examiner Signature

Date Considered

6/29/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of


8

**Complete if Known**

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		BUTTERS, et al., "Isolation and Characterization of Mosquito Cell Membrane Glycoproteins", Biochimica et Biophysica Acta, 1981, Vol. 640, pp. 655-671.		
		CHOUARDY, P.V. et al., "Retrovirus-mediated Transfer of the Human Glucocerebrosidase Gene to Gaucher Fibroblasts", Mol. Biol. Med., 1986, Vol. 3, pp. 293-299.		
		CHOUARDY, P.V. et al., "The Molecular Biology of Gaucher Disease and the Potential for Gene Therapy", Cold Spring Harbor Symposia on Quantitative Biology, Volume LI, 1986, PP. 1047-1052.		
		CHOUARDY, P.V. et al., "Gene Transfer of Human Glucocerebrosidase cDNA to Gaucher Fibroblasts: Expression of the Epitope Altered in Type 2 Phenotype", DNA, 1986, Vol. 5, No. 1, p. 78.		
		CHOUARDY, P.V. et al., "Gene Transfer and Expression of Active Human Glucocerebrosidase in Mammalian Cell Cultures", DNA, 1986, Vol. 5, No. 1, p. 78.		
		CORRELL, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells", Proc. Natl. Acad. Sci. USA, 1989, Vol. 86, pp. 8912-8916.		
		CREIGHTON, T.E., "Disulfide Bond Formation in Proteins", Methods in Enzymology, 1984, Vol. 107, pp. 305-329.		
		DAS, P.K. et al., "Lectin-Specific Targeting of β-Glucocerebrosidase to Different Liver Cells via Glycosylated Liposomes", Biochemical Medicine, 1985, Vol. 33, pp. 124-131.		
		FRESHNEY, R.I., "Culture of Animal Cells, A Manual of Basic Technique", Alan R. Liss, Inc. New York, Second Edition, p. 69.		
		FRIEDMAN, B. et al., "A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived β-Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease", Blood, 1999, Vol. 93, No. 9, pp. 2807-2816.		
		FURBISH, F.S. et al., "Uptake and Distribution of Placental Glucocerebrosidase in Rat Hepatic Cells and Effects of Sequential Deglycosylation", Biochimica et Biophysica Acta, 1981, Vol. 673, pp. 425-434.		

Examiner Signature



Date Considered

6/29/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				<i>Application Number</i>	10/814,025
				<i>Filing Date</i>	March 31, 2004
				<i>First Named Inventor</i>	Rasmussen et al.
				<i>Art Unit</i>	1636
				<i>Examiner Name</i>	Sullivan, Daniel M.
Sheet	4	of	8	Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
DS		FURBISH, F.S. et al., "Enzyme replacement therapy in Gaucher's disease: Large-scale purification of glucocerebrosidase suitable for human administration", Proc. Natl. Acad. Sci. USA, 1977, Vol. 74, No. 8, pp. 3560-3563.		
		FURBISH, F.S. et al., "Lysosomal Targeting of an Exogeneously Supplied Lysosomal Enzyme", Fed. Proc., 1983, Vol. 42, p. 394.		
		GORMAN C., "High Efficiency Gene Transfer in Mammalian Cells", DNA Cloning-A Practical Approach (IRL Press, Washington, DC), 1985, Vol. 11, pp. 143-165.		
		HAM, R.G. et al., "Media and Growth Requirements", Methods in Enzymology, Academic Press, New York, 1979, Vol. LVIII, pp. 72-74.		
		HOUDEBINE, L.M., "Transgenic animal bioreactors", Transgenic Research, 2000, Vol. 9, pp. 305-320.		
		HSIEH, P. et al., "Regulation of Asparagine-linked Oligosaccharide Processing", The Journal of Biological Chemistry, 1984, Vol. 259, No. 4, pp. 2375-2382.		
		HUMPHREYS, J.D. et al., "Enhanced stability of erythrocyte-entrapped glucocerebrosidase activity", J. Lab. Clin. Med., 1980, Vol. 96, Issue 4, pp. 682-692.		
		JAY, G. et al., "Identification of the SV40 agnogene product: a DNA binding protein", Nature, 1981, Vol. 291, pp. 346-349.		
		JOHANSEN, H. et al., "Affecting gene expression by altering the length and sequence of the 5' leader", Proc. Natl. Acad. Sci. USA, 1984, Vol. 81, pp. 7698-7702.		
		KAUFMAN, R.J., "High Level Production of Proteins in Mammalian Cells", Genetic Engineering, 1987, Vol. 9, pp. 155-198.		
DS		KAUFMAN, R.J. et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells", The EMBO Journal, 1987, Vol. 6, No. 1, pp. 187-193.		

Examiner Signature		Date Considered	6/29/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/814,025
				Filing Date	March 31, 2004
				First Named Inventor	Rasmussen et al.
				Art Unit	1636
				Examiner Name	Sullivan, Daniel M.
Sheet	5	of	8	Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		KAUFMAN, R.J. et al., "Expression, Purification, and Characterization of Recombinant $\gamma$ -Carboxylated Factor IX Synthesized in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, 1986, Vol. 261, No. 21, pp. 9622-9628.		
		KOHN, D.B. et al., "Human Glucocerebrosidase Gene Transfer by Retroviral Vectors", Ped. Res., 1989, Vol. 25, No. 4, Part 2, 852, p. 145a.		
		KOZAK, M., "Bifunctional Messenger RNAs in Eukaryotes", Cell, 1986, Vol. 47, No. 4, pp. 481-483.		
		LIU, C.C. et al., "Initiation of translation at internal AUG codons in mammalian cells", Nature, 1984, Vol. 309, No. 5963, pp. 82-85.		
		LUCKOW, V.A. et al., "Trends in the Development of Baculovirus Expression Vectors", Bio/Technology, 1988, Vol. 6, pp. 47-55.		
		MacMICHAEL, G.J., "The effect of pH and oxygen on the growth, monoclonal antibody production, and metabolism of a mouse hybridoma", Amer. Biotech. Lab, 1989, pp. 44-47.		
		MAEDA, S. et al., "Production of human $\alpha$ -interferon in silkworm using a baculovirus vector", Nature, 1985, Vol. 315, pp. 592-594.		
		MAIORELLA, B. et al., "Optimized PH Control for Antibody Production", ACS National Fall Meeting, Miami, abstract, 1989.		
		MARTIN, B.M., "Glycosylation and Processing of High Levels of Active Human Glucocerebrosidase in Invertebrate Cells Using a Baculovirus Expression Vector", DNA, 1988, Vol. 7, No. 2, pp. 99-106.		
		MILLER, W.M. et al., "Effects of Dissolved Oxygen Concentration on Hybridoma Growth and Metabolism in Continuous Culture", J. Cell. Physiol., 1987, Vol. 132, pp. 524-530.		
		MURRAY, G.J. et al., "Lectin-Specific Targeting of Lysosomal Enzymes to Reticuloendothelial Cells", Meth. in Enzymol., 1987, Vol. 149, pp. 25-42.		

Examiner Signature		Date Considered	6/29/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/814,025
				Filing Date	March 31, 2004
				First Named Inventor	Rasmussen et al.
				Art Unit	1636
				Examiner Name	Sullivan, Daniel M.
				Attorney Docket Number	GC22.4-CON2
Sheet 6		of 8			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		NORDIN, J.H. et al., "A Comparative Study of the Size-Heterogeneous High Mannose Oligosaccharides of Some Insect Vitellins", Biochem. Physiol., 1984, Vol. 798, No. 3, pp. 379-390.		
		PEABODY, D.S. et al., "Termination-Reinitiation Occurs in the Translation of Mammalian Cell mRNAs", Molecular and Cellular Biology, 1986, Vol. 6, No. 7, pp. 2695-2703.		
		PEABODY, D.S. et al., "Effect of Upstream Reading Frames on Translation Efficiency in Simian Virus 40 Recombinants", Molecular and Cellular Biology, 1986, Vol. 6, No. 7, pp. 2704-2711.		
		PENTCHEV, P.G. et al., "Isolation and Characterization of Glucocerebrosidase from Human Placental Tissue", J. Biol Chem, 1973, Vol. 248, No. 15, pp. 5256-5261.		
		PUGH, G.G., "The Role of Oxygen Consumption Rate in Bioreactor Process Control", Bio/Technology, 1988, Vol. 6, pp. 524-526.		
		REINER, O. et al., "Efficient <i>In Vitro</i> and <i>In Vivo</i> Expression of Human Glucocerebrosidase cDNA", DNA, 1987, Vol. 6, No. 2, pp. 101-108.		
		REUVENY, S. et al., "Factors affecting cell growth and monoclonal antibody production in stirred reactors", J. Immunolog. Meth., 1986, Vol. 86, pp. 53-59.		
		RHODES, M., "Large-Scale Production of Proteins from Mammalian Cells", Biotechnology, 1988, Vol. 6, pp. 518-526.		
		SIGMA CELL CULTURE REAGENTS, Catalog/Price List, 1990 pp. 224-225 and pp. 220-221		
		SORGE, J. et al., "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA", Proc. Natl. Acad. Sci. USA, 1985, Vol. 82, pp. 7289-7293.		
		SORGE, J. et al., [Correction notice], Proc. Natl. Acad. Sci. USA, 1986, Vol. 83, p. 3567.		

Examiner Signature		Date Considered	6/29/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/814,025
				Filing Date	March 31, 2004
				First Named Inventor	Rasmussen et al.
				Art Unit	1636
				Examiner Name	Sullivan, Daniel M.
Sheet	7	of	8	Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		SORGE, J. et al., "Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer", Proc. Natl. Acad. Sci. USA, 1987, Vol. 84, pp. 906-909.		
		SORGE, J. et al., "The Human Glucocerebrosidase Gene Has Two Functional ATG Initiator Codons", Am. J. Human Genetics, 1987, Vol. 41, pp. 1016-1024.		
		SORGE, J. et al., "Gaucher Disease: Retrovirus-mediated Correction of the Enzymatic Defect in Cultured Cells", Cold Spring Harbor Symposia on Quantitative Biology, 1986, Vol. LI, pp. 1041-1046.		
		STAHL, P.D. et al., "Evidence for receptor-mediated binding of glycoproteins, glucoconjugates, and Lysosomal glycosidases by alveolar macrophages", Proc Natl Acad Sci USA, 1978, Vol. 75, No. 3, pp. 1399-1403.		
		SUBRAMANI, S. et al., "Expression of The Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors", Molecular and Cellular Biology, 1981, Vol. 1, pp. 854-864.		
		SUZUKI, K., "Degradation", Methods in Enzymol., 1978, Vol. 50, pp. 478-479.		
		TREMBLAY, P.J. et al., "Transgenic Mice Carrying the Mouse Mammary Tumor Virus ras Fusion Gene: Distinct Effects in Various Tissues", Molecular and Cellular Biology, 1989, Vol. 9, No. 2, pp. 854-859.		
		TRIVEDI, L.S. et al., "Normal and Warfarin-Resistant Rat Hepatocyte Metabolism of Vitamin K 2,3-Epoxide: Evidence for Multiple Pathways of Hydroxyvitamin K Formation", Arch. Biochem Biophys., 1988, Vol. 264, pp. 67-73.		
		TSUJI, S. et al., "Nucleotide Sequence of cDNA Containing the Complete Coding Sequence for Human Lysosomal Glucocerebrosidase", The Journal of Biological Chemistry, 1986, Vol. 261, Issue 1, pp. 50-53.		
		URLAUB, G. et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions", Som. Cell Molec. Genet., 1986, Vol. 12, No. 6, pp. 555-566.		
		Van WEZEL, A.L. et al., "Large Scale Cultivation of Animal Cells in Microcarrier Culture", Process Biochemistry, 1978, pp. 6-8.		


Examiner Signature		Date Considered	6/29/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/814,025
				<i>Filing Date</i>	March 31, 2004
				<i>First Named Inventor</i>	Rasmussen et al.
				<i>Art Unit</i>	1636
				<i>Examiner Name</i>	Sullivan, Daniel M.
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	GC22.4-CON2
Sheet	8	of	8		

Examiner Signature		Date Considered	6/29/05
--------------------	---	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.